The impact of insulin resistance and NAFLD after liver transplantation on patient survival and development of chronic kidney disease

Q4 Medicine
I. Mikova, Denisa Kyselová, K. Dvor̆áková, M. Dezortova, M. Hájek, M. Cahova, H. Daňková, V. Lánská, J. Spicak, P. Trunec̃ka
{"title":"The impact of insulin resistance and NAFLD after liver transplantation on patient survival and development of chronic kidney disease","authors":"I. Mikova, Denisa Kyselová, K. Dvor̆áková, M. Dezortova, M. Hájek, M. Cahova, H. Daňková, V. Lánská, J. Spicak, P. Trunec̃ka","doi":"10.48095/ccgh2022429","DOIUrl":null,"url":null,"abstract":"Summary: Introduction: Insulin resistance (IR) is a hallmark of non-alcoholic fatty liver disease (NAFLD), which has been associated with worse long-term survival and more frequent occurrence of chronic kidney disease (CKD) than in patients without NAFLD. The aim of our study was to evaluate the impact of NAFLD and IR on survival and renal function in patients after liver transplantation (LT). Methods: Our prospective study included 96 LT candidates who were observed after LT. We evaluated patient survival and occurrence of CKD (defined as estimated glomerular filtration [eGFR] ≤1.00 mL/s/1.73 m2 or overt proteinuria) 5 years after LT and at the end of follow-up. Clinical, laboratory, MR and elastographic evaluation before and 1 year after LT were performed as well as liver biopsy 1 year after LT. Results: Of the factors present 1 year after LT, higher ALT (P = 0.021), ALP (P = 0.012) and everolimus treatment (P = 0.025) increased the risk of death at the end of follow-up, borderline significance was found also for higher waist circumference (P = 0.058), AST (P = 0.059), HOMA-IR (P = 0.056) and presence of fibrosis stage ≥3 in biopsy (P = 0.055). In addition to the presence of CKD 1 year after LT (P <0.001), other independent posttransplant risk factors of CKD 5 years after LT included presence of IR defined as HOMA-IR ≥3 (OR 4.33; 95% CI 1.25–15.04; P = 0.021) and higher serum high-molecular-weight (HMW) adiponectin (OR 1.25; 95% CI 1.03–1.50; P = 0.021). Of the factors present 1 year after LT, diabetes treated by antidiabetics (P = 0.008), higher serum levels od triglycerides (P = 0.031), C-peptide (P = 0.022) and leptin (P = 0.002) and lower total bilirubin (P = 0.006) were associated with lower eGFR at the end of follow-up. We observed a trend towards higher eGFR levels in patients treated with everolimus (P = 0.055). We did not observe an impact of grade of steatosis and presence of steatohepatitis on biopsy 1 year after LT on survival or renal functions. Conclusion: Presence of IR 1 year after LT independently increased the risk of CKD 5 year after LT. Patients with higher HOMA-IR 1 year after LT had a trend towards worse survival at the end of follow-up. Key words: insulin resistance – non-alcoholic fatty liver disease – liver transplantation – chronic kidney disease – survival","PeriodicalId":38577,"journal":{"name":"Gastroenterologie a Hepatologie","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologie a Hepatologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48095/ccgh2022429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Summary: Introduction: Insulin resistance (IR) is a hallmark of non-alcoholic fatty liver disease (NAFLD), which has been associated with worse long-term survival and more frequent occurrence of chronic kidney disease (CKD) than in patients without NAFLD. The aim of our study was to evaluate the impact of NAFLD and IR on survival and renal function in patients after liver transplantation (LT). Methods: Our prospective study included 96 LT candidates who were observed after LT. We evaluated patient survival and occurrence of CKD (defined as estimated glomerular filtration [eGFR] ≤1.00 mL/s/1.73 m2 or overt proteinuria) 5 years after LT and at the end of follow-up. Clinical, laboratory, MR and elastographic evaluation before and 1 year after LT were performed as well as liver biopsy 1 year after LT. Results: Of the factors present 1 year after LT, higher ALT (P = 0.021), ALP (P = 0.012) and everolimus treatment (P = 0.025) increased the risk of death at the end of follow-up, borderline significance was found also for higher waist circumference (P = 0.058), AST (P = 0.059), HOMA-IR (P = 0.056) and presence of fibrosis stage ≥3 in biopsy (P = 0.055). In addition to the presence of CKD 1 year after LT (P <0.001), other independent posttransplant risk factors of CKD 5 years after LT included presence of IR defined as HOMA-IR ≥3 (OR 4.33; 95% CI 1.25–15.04; P = 0.021) and higher serum high-molecular-weight (HMW) adiponectin (OR 1.25; 95% CI 1.03–1.50; P = 0.021). Of the factors present 1 year after LT, diabetes treated by antidiabetics (P = 0.008), higher serum levels od triglycerides (P = 0.031), C-peptide (P = 0.022) and leptin (P = 0.002) and lower total bilirubin (P = 0.006) were associated with lower eGFR at the end of follow-up. We observed a trend towards higher eGFR levels in patients treated with everolimus (P = 0.055). We did not observe an impact of grade of steatosis and presence of steatohepatitis on biopsy 1 year after LT on survival or renal functions. Conclusion: Presence of IR 1 year after LT independently increased the risk of CKD 5 year after LT. Patients with higher HOMA-IR 1 year after LT had a trend towards worse survival at the end of follow-up. Key words: insulin resistance – non-alcoholic fatty liver disease – liver transplantation – chronic kidney disease – survival
肝移植后胰岛素抵抗和NAFLD对慢性肾病患者生存和发展的影响
摘要:胰岛素抵抗(IR)是非酒精性脂肪性肝病(NAFLD)的一个标志,与非NAFLD患者相比,NAFLD患者的长期生存期更差,慢性肾脏疾病(CKD)的发生频率更高。本研究的目的是评估NAFLD和IR对肝移植术后患者生存和肾功能的影响。方法:我们的前瞻性研究包括96名LT后观察的LT候选人。我们评估了LT后5年和随访结束时患者的生存和CKD的发生(定义为肾小球滤过率[eGFR]≤1.00 mL/s/1.73 m2或明显蛋白尿)。临床、实验室、先生和elastographic评估之前和肝移植后1年进行以及肝脏活组织检查后1年中将结果:LT的因素现在1年后,更高的ALT (P = 0.021),高山(P = 0.012)和everolimus治疗(P = 0.025)增加死亡的风险在最后的随访中,临界意义被发现也为更高的腰围(P = 0.058), AST (P = 0.059), HOMA-IR (P = 0.056)和存在纤维化阶段≥3活检(P = 0.055)。除了肝移植后1年存在CKD (P <0.001)外,肝移植后5年CKD的其他独立危险因素包括IR的存在,定义为HOMA-IR≥3 (OR 4.33;95% ci 1.25-15.04;P = 0.021),血清高分子量(HMW)脂联素升高(OR 1.25;95% ci 1.03-1.50;P = 0.021)。在肝移植后1年存在的因素中,接受抗糖尿病治疗的糖尿病(P = 0.008)、血清中较高的甘油三酯(P = 0.031)、c肽(P = 0.022)和瘦素(P = 0.002)水平和较低的总胆红素(P = 0.006)水平与随访结束时较低的eGFR相关。我们观察到依维莫司治疗的患者eGFR水平有升高的趋势(P = 0.055)。我们没有观察到肝移植后1年活检中脂肪变性程度和脂肪性肝炎的存在对生存或肾功能的影响。结论:肝移植后1年存在IR单独增加了肝移植后5年发生CKD的风险。肝移植后1年HOMA-IR较高的患者在随访结束时生存率有较差的趋势。关键词:胰岛素抵抗;非酒精性脂肪肝;肝移植
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gastroenterologie a Hepatologie
Gastroenterologie a Hepatologie Medicine-Gastroenterology
CiteScore
0.40
自引率
0.00%
发文量
32
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信